Sysmex (OTCMKTS:SSMXY) Shares Gap Up – Time to Buy?

Sysmex Corporation ADR (OTCMKTS:SSMXY) shares gapped up before the market opened on Thursday . The stock had previously closed at $8.46, but opened at $8.81. Sysmex shares last traded at $8.6050, with a volume of 19,589 shares.

Analyst Ratings Changes

Separately, Citigroup cut shares of Sysmex from a “strong-buy” rating to a “hold” rating in a report on Monday, March 16th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, Sysmex presently has a consensus rating of “Hold”.

Sysmex Stock Up 0.8%

The company has a debt-to-equity ratio of 0.12, a current ratio of 3.33 and a quick ratio of 2.44. The stock has a fifty day moving average price of $9.11 and a two-hundred day moving average price of $10.25. The company has a market cap of $5.33 billion, a P/E ratio of 17.65 and a beta of 1.14.

Sysmex (OTCMKTS:SSMXY) last announced its earnings results on Thursday, February 12th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.01. The company had revenue of $837.32 million for the quarter, compared to analysts’ expectations of $819.99 million. Sysmex had a return on equity of 9.27% and a net margin of 8.86%. On average, research analysts expect that Sysmex Corporation ADR will post 0.57 EPS for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.